- Published on
Infectious Disease - Cystitis
CYSTITIS
ESSENTIALS DESCRIPTION
Both men and women can get cystitis, a lower urinary tract infection (UTI) that affects the bladder.
The study of epidemiology
The prevalence
• In the US, there are 7 million UTI cases each year.
• Roughly one-third of women aged 24 and older will experience at least one UTI episode that necessitates antibiotic therapy (1).
• Within the first year, around half of the women whose simple UTIs go away on their own will get another UTI (2).
The frequency
more common in young women (20% vs. 0.5%, respectively, ages 16–35) than in young men.
RISK FACTORS • Premenopausal women: spermicide use, diaphragm contraception, increasing parity, diabetes mellitus, pregnancy, obesity, neurologic diseases, history of urinary tract infections, anatomic congenital abnormalities, frequent or recent sexual activity, and medical conditions requiring indwelling or repetitive bladder catheterization (3).
UTI history, vaginal atrophy, inadequate bladder emptying, rectocele, cystocele, urethrocele, uterovaginal prolapse, and type 1 diabetes are all present in postmenopausal women (3).
Men: incontinence, surgery, catheterization, urethral blockage, and prostate hypertrophy.
•
For general prevention, practice good atomic hygiene, refrain from using diaphragms, get regular urine tests in the third trimester of pregnancy, and avoid glycosuria if you have diabetes.
ETIOLOGY • The most frequent cause (~>80%) is Escherichia coli.
Proteus mirabilis, Enterobacter species, Citrobacter species, Serratia species, Klebsiella species, Salmonella species, and Morganella morganii are examples of other Enterobacteriaceae. Pseudomonas aeruginosa is an example of a non-Enterobacteriaceae species.
• Another significant issue is the rise of uropathogens, primarily E. coli, that cause nosocomial and community-acquired cystitis and have a notably high level of resistance because they produce extended-spectrum -lactamases (ESBLs) (4). • Saprophyticus Staphylococcus
History of Diagnosis
• Ten percent of patients have low back discomfort, suprapubic tenderness, murky urine, sudden onset, frequency, urgency, and occasionally bloody or foul-smelling urine.
• Kids: General symptoms (diarrhea, vomiting, fever, etc.)
• Older adults: Few symptoms
MEDICAL EXAMINATION
Tenderness in the suprapubic region
Tests for Diagnosis and Interpretation Lab
Urine microscopy, urine culture, and urinary dipstick testing (which detects nitrites and leukocyte esterase in the urine)
• Examine if a pregnancy test is required.
Imagining
• Male ultrasound
• If a young woman experiences recurrent episodes unrelated to coitus or does not respond to antibiotic treatment (as indicated by in vitro antibiotic susceptibility data), consider ultrasonography.
Diagnostic Techniques and Other
Urodynamic examination. Nevertheless, there is little evidence to support the claim that urodynamic testing is helpful in identifying particular urogynecologic mechanisms that would have helped prevent or enhance the medicinal and/or surgical treatment of recurrent UTIs (5).
• Bladder biopsies, cystoscopy, and urography. However, the usefulness of cystoscopy can be regarded as somewhat limited because patients with cystitis rarely experience morphological and/or functional abnormalities of the urinary system (6).
• x-rays of the bladder
DISTINCTIVE DIAGNOSIS
• Contagious: urethritis, vaginitis, silent bacteriuria, and pyelonephritis (upper UTI).
Interstitial cystitis, urolithiasis, bladder tumors, and chronic prostatitis/chronic pelvic pain syndrome are examples of noninfectious conditions.
MEDICATION FOR TREATMENT
Cystitis Recurrent
It has been proposed that a 95% reduction in the risk of recurrence can be achieved by continuous prophylaxis with once-daily treatment with norfloxacin, ciprofloxacin, trimethoprim (TMP), trimethoprim–sulfamethoxazole (TMP-SMX), or nitrofurantoin (8). However, such a strategy needs to be tailored in this day and age due to the startlingly high levels of antibiotic resistance in uropathogens.
Acute Uncomplicated Cystitis • Oral twice daily for three days of trimethoprim-sulfamethoxazole (TMP-SMX): TMP: 160 mg-SMX: 800 mg
• Ciprofloxacin: 250 mg twice daily for three days; Levofloxacin: 250 mg once daily for three days; Norfloxacin: 400 mg twice daily for three days; TMP: 100 mg twice daily for three days; and Fosfomycin tromethamine: 3 g oral single dose (3,7)
• Nitrofurantoin macrocrystals: four times a day, 50–100 mg
for seven days
• 100 mg twice a day for seven days of nitrofurantoin monohydrate macrocrystals (3) Considerations for Pregnancy
For three days, take 250 mg of amoxicillin every eight hours, 100 mg of microcrystalline nitrofurantoin four times a day, and 200 mg of cefpodoxime twice a day. Because it may cause hemolysis in the fetus or newborn, avoid administering it during labor or obstetric delivery as well as in late pregnancy (38–42 weeks). Given that adverse effects appear to be substantially less common in pregnant women treated with fosfomycin than in those treated with other antibiotics, fosfomycin may also be useful in the treatment of cystitis during pregnancy (7).
COMPLEMENTARY & ALTERNATIVE THERAPIES • Probiotics: Studies have demonstrated that Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 are the most effective lactobacilli for preventing urinary tract infections. Significant effectiveness has also been demonstrated by L. crispatus CTV-05 and L. casei shirota. On the
However, it has been demonstrated that L. rhamnosus GG is not as successful in preventing UTIs (9).
• Cranberry juice: It may help treat and/or prevent UTIs because it has been proposed to be a strong inhibitor of bacterial adhesion (10). In example, cranberry juice has been shown to have the potential to lower the number of symptomatic UTIs over a 12-month period, especially for women who experience recurrent UTIs (11).
• Methenamine salts (methenamine hippurate): In individuals without urinary tract abnormalities, methenamine hippurate medication for a brief period of time (≤1 week) has been linked to a significant decrease in symptomatic UTI. Nevertheless, patients with neuropathic bladder or urinary tract disorders do not seem to benefit from them (12).
• Uroanalgesics: The goal of giving uroanalgesics, like phenazopyridine, to individuals who are experiencing acute cystitis symptoms is to alleviate their symptoms. The mucosa of the bladder may experience analgesia from phenazopyridine. Additionally, it has been proposed that its antibacterial action is increased when administered in conjunction with sulfonamides (13). Nonetheless, numerous research indicated that phenazopyridine can be linked to negative side effects, such as
anemia due to hemolysis (14).
• There is still inadequate data to support the idea that intensive hydration can effectively avoid recurrent cystitis.
• There is also mixed evidence about the efficacy of oral and vaginal exogenous estrogens in preventing recurrent UTIs in postmenopausal women (15).
OTHER PROCEDURES AND SURGERY
Surgical correction of urinary tract anatomical defects
PROGNOSIS FOR ONGOING CARE: Most patients with acute, uncomplicated cystitis have a very good prognosis with proper antibiotic treatment.
• Nevertheless, patients without complications or those with risk factors (such anomalies of the urinary system) may experience recurrent cystitis.
Pyelonephritis, urethritis, and mental illnesses, especially following recurrent cystitis
CYSTITIS
ESSENTIALS DESCRIPTION
Both men and women can get cystitis, a lower urinary tract infection (UTI) that affects the bladder.
The study of epidemiology
The prevalence
• In the US, there are 7 million UTI cases each year.
• Roughly one-third of women aged 24 and older will experience at least one UTI episode that necessitates antibiotic therapy (1).
• Within the first year, around half of the women whose simple UTIs go away on their own will get another UTI (2).
The frequency
more common in young women (20% vs. 0.5%, respectively, ages 16–35) than in young men.
RISK FACTORS • Premenopausal women: spermicide use, diaphragm contraception, increasing parity, diabetes mellitus, pregnancy, obesity, neurologic diseases, history of urinary tract infections, anatomic congenital abnormalities, frequent or recent sexual activity, and medical conditions requiring indwelling or repetitive bladder catheterization (3).
UTI history, vaginal atrophy, inadequate bladder emptying, rectocele, cystocele, urethrocele, uterovaginal prolapse, and type 1 diabetes are all present in postmenopausal women (3).
Men: incontinence, surgery, catheterization, urethral blockage, and prostate hypertrophy.
•
For general prevention, practice good atomic hygiene, refrain from using diaphragms, get regular urine tests in the third trimester of pregnancy, and avoid glycosuria if you have diabetes.
ETIOLOGY • The most frequent cause (~>80%) is Escherichia coli.
Proteus mirabilis, Enterobacter species, Citrobacter species, Serratia species, Klebsiella species, Salmonella species, and Morganella morganii are examples of other Enterobacteriaceae. Pseudomonas aeruginosa is an example of a non-Enterobacteriaceae species.
• Another significant issue is the rise of uropathogens, primarily E. coli, that cause nosocomial and community-acquired cystitis and have a notably high level of resistance because they produce extended-spectrum -lactamases (ESBLs) (4). • Saprophyticus Staphylococcus
History of Diagnosis
• Ten percent of patients have low back discomfort, suprapubic tenderness, murky urine, sudden onset, frequency, urgency, and occasionally bloody or foul-smelling urine.
• Kids: General symptoms (diarrhea, vomiting, fever, etc.)
• Older adults: Few symptoms
MEDICAL EXAMINATION
Tenderness in the suprapubic region
Tests for Diagnosis and Interpretation Lab
Urine microscopy, urine culture, and urinary dipstick testing (which detects nitrites and leukocyte esterase in the urine)
• Examine if a pregnancy test is required.
Imagining
• Male ultrasound
• If a young woman experiences recurrent episodes unrelated to coitus or does not respond to antibiotic treatment (as indicated by in vitro antibiotic susceptibility data), consider ultrasonography.
Diagnostic Techniques and Other
Urodynamic examination. Nevertheless, there is little evidence to support the claim that urodynamic testing is helpful in identifying particular urogynecologic mechanisms that would have helped prevent or enhance the medicinal and/or surgical treatment of recurrent UTIs (5).
• Bladder biopsies, cystoscopy, and urography. However, the usefulness of cystoscopy can be regarded as somewhat limited because patients with cystitis rarely experience morphological and/or functional abnormalities of the urinary system (6).
• x-rays of the bladder
DISTINCTIVE DIAGNOSIS
• Contagious: urethritis, vaginitis, silent bacteriuria, and pyelonephritis (upper UTI).
Interstitial cystitis, urolithiasis, bladder tumors, and chronic prostatitis/chronic pelvic pain syndrome are examples of noninfectious conditions.
MEDICATION FOR TREATMENT
Cystitis Recurrent
It has been proposed that a 95% reduction in the risk of recurrence can be achieved by continuous prophylaxis with once-daily treatment with norfloxacin, ciprofloxacin, trimethoprim (TMP), trimethoprim–sulfamethoxazole (TMP-SMX), or nitrofurantoin (8). However, such a strategy needs to be tailored in this day and age due to the startlingly high levels of antibiotic resistance in uropathogens.
Acute Uncomplicated Cystitis • Oral twice daily for three days of trimethoprim-sulfamethoxazole (TMP-SMX): TMP: 160 mg-SMX: 800 mg
• Ciprofloxacin: 250 mg twice daily for three days; Levofloxacin: 250 mg once daily for three days; Norfloxacin: 400 mg twice daily for three days; TMP: 100 mg twice daily for three days; and Fosfomycin tromethamine: 3 g oral single dose (3,7)
• Nitrofurantoin macrocrystals: four times a day, 50–100 mg
for seven days
• 100 mg twice a day for seven days of nitrofurantoin monohydrate macrocrystals (3) Considerations for Pregnancy
For three days, take 250 mg of amoxicillin every eight hours, 100 mg of microcrystalline nitrofurantoin four times a day, and 200 mg of cefpodoxime twice a day. Because it may cause hemolysis in the fetus or newborn, avoid administering it during labor or obstetric delivery as well as in late pregnancy (38–42 weeks). Given that adverse effects appear to be substantially less common in pregnant women treated with fosfomycin than in those treated with other antibiotics, fosfomycin may also be useful in the treatment of cystitis during pregnancy (7).
COMPLEMENTARY & ALTERNATIVE THERAPIES • Probiotics: Studies have demonstrated that Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 are the most effective lactobacilli for preventing urinary tract infections. Significant effectiveness has also been demonstrated by L. crispatus CTV-05 and L. casei shirota. On the
However, it has been demonstrated that L. rhamnosus GG is not as successful in preventing UTIs (9).
• Cranberry juice: It may help treat and/or prevent UTIs because it has been proposed to be a strong inhibitor of bacterial adhesion (10). In example, cranberry juice has been shown to have the potential to lower the number of symptomatic UTIs over a 12-month period, especially for women who experience recurrent UTIs (11).
• Methenamine salts (methenamine hippurate): In individuals without urinary tract abnormalities, methenamine hippurate medication for a brief period of time (≤1 week) has been linked to a significant decrease in symptomatic UTI. Nevertheless, patients with neuropathic bladder or urinary tract disorders do not seem to benefit from them (12).
• Uroanalgesics: The goal of giving uroanalgesics, like phenazopyridine, to individuals who are experiencing acute cystitis symptoms is to alleviate their symptoms. The mucosa of the bladder may experience analgesia from phenazopyridine. Additionally, it has been proposed that its antibacterial action is increased when administered in conjunction with sulfonamides (13). Nonetheless, numerous research indicated that phenazopyridine can be linked to negative side effects, such as
anemia due to hemolysis (14).
• There is still inadequate data to support the idea that intensive hydration can effectively avoid recurrent cystitis.
• There is also mixed evidence about the efficacy of oral and vaginal exogenous estrogens in preventing recurrent UTIs in postmenopausal women (15).
OTHER PROCEDURES AND SURGERY
Surgical correction of urinary tract anatomical defects
PROGNOSIS FOR ONGOING CARE: Most patients with acute, uncomplicated cystitis have a very good prognosis with proper antibiotic treatment.
• Nevertheless, patients without complications or those with risk factors (such anomalies of the urinary system) may experience recurrent cystitis.
Pyelonephritis, urethritis, and mental illnesses, especially following recurrent cystitis
0 Comments
